Contrast-induced nephropathy-choice of contrast agents to reduce renal risk

American Heart Hospital Journal

Volumn 7, Issue 1, 2009, Pages 45-49

  Katholi, Richard E ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; CONTRAST MEDIUM; CREATININE; IODIXANOL; IOHEXOL; IOPAMIDOL; IOVERSOL; MITOCHONDRIAL ENZYME; IODOBENZOIC ACID DERIVATIVE;

ANGIOGRAPHY; CLINICAL TRIAL (TOPIC); CONTRAST INDUCED NEPHROPATHY; CORONARY ANGIOGRAPHY; DRUG EFFICACY; DRUG ELIMINATION; DRUG RESPONSE; DRUG SAFETY; ENZYME ACTIVITY; ESTIMATED GLOMERULAR FILTRATION RATE; HIGH RISK PATIENT; HUMAN; INCIDENCE; KIDNEY FAILURE; KIDNEY PROXIMAL TUBULE; PATHOGENESIS; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SKIN MANIFESTATION; CHEMICALLY INDUCED DISORDER; CHEMISTRY; KIDNEY DISEASE; KIDNEY FUNCTION TEST; OSMOLARITY; RISK ASSESSMENT;

CONTRAST MEDIA; HUMANS; IOPAMIDOL; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; OSMOLAR CONCENTRATION; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; TRIIODOBENZOIC ACIDS;

EID: 73949105560     PISSN: 15419215     EISSN: 17517168     Source Type: Journal    
DOI: 10.15420/ahhj.2009.7.1.45     Document Type: Review

References (26)

1. Nash K, Hafeez A, Hou S, Hospital-acquired renal insufficiency, Am J Kidney Dis, 2002;39:930-36
2. McCullough PA, Adam A, Becker CR, et al. on behalf of the CIN Consensus Working Panel, Epidemiology and prognostic implications of contrast-induced nephropathy, Am J Cardiol, 2006;98(Suppl.):5K-13K
3. Tumlin J, Stacul F, Adam A, et al. on behalf of the CIN Consensus Working Panel. Pathophysiology of contrast-induced nephropathy, Am J Cardiol, 2006;98(Suppl.):14K-20K
4. Katholi RE, Contrast-induced nephropathy-update and practical clinical applications, US Cardiovascular Disease, 2006;(II):73-80
5. Stacul F, Adam A, Becker CR, et al. CIN Consensus Working Panel, Strategies to reduce the risk of contrast-induced nephropathy, Am J Cardiol, 2006;98(Suppl.):59K-77K
6. Wyatt C, Konduri V, Eng J, et al. Reporting of estimated GFR in the primary care clinic, Am J Kidney Dis, 2007;49:634-41
7. Merten GJ, Burgass WP, Gray LV, et al. Prevention of contrastinduced nephropathy with sodium bicarbonate, JAMA, 2004;291: 2328-34
8. Hardiek K, Katholi RE, Ramkumar V, et al. Proximal tubule cell response to radiographic contrast media, Am J Physiol Renal Physiol, 2001;280:F61-F70
9. Mehran R, Nikolsky E, Contrast-induced nephropathy: definition, epidemiology, and patients at risk, Kidney Int Suppl, 2006;(100):S11-S15
10. Solomon R, The role of osmolality in the incidence of contrastinduced nephropathy: a systematic review of angiographic contrast media in high risk patients, Kidney Int, 2005;68:2256-63
11. Taliercio CP, Vlietstra RE, Ilstrup DM, et al. A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography, J Am Coll Cardiol, 1991;17:384-90
12. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The iohexol cooperative study, Kidney Int, 1995;47:254-61
13. Aspelin P, Aubry P, Fransson SG, et al. for the Nephrotoxicity in High-Risk Patients Study of Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media Study Investigators, Nephrotoxic effects in high-risk patients undergoing angiography, N Engl J Med, 2003;348:491-9
14. Chalmers N, Jackson RW, Comparison of iodixanol and iohexol in renal impairment, Br J Radiol, 1999;72:701-3
15. Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between Visipaque (iodixanol) and Hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial, J Am Coll Cardiol, 2006;48:924-30
16. Mehran R; ICON Investigators, Ionic versus non-ionic contrast to obviate worsening nephropathy after angioplasty in chronic renal failure patients. Abstract presented at Transcatheter Cardiovascular Therapeutics meeting, Washington, DC, October 22-27, 2006
17. Rudnick M, Contrast media induced nephrotoxicity. Presented at: American Society of Nephrology Clinical Nephrology Conferences, Philadelphia, PA, November 8-13, 2005;353
18. Solomon RJ, Natarajan MK, Doucet S, et al. Investigators of the CARE study. Cardiac Angiography in Renally impaired patients (CARE) study: a randomized, double-blind trial of contrastinduced nephropathy in high risk patients, Circulation, 2007;115:3189-96
19. Solomon R, Du Mouchel W, Contrast media and nephropathy: findings from systematic analysis and food and drug administration reports of adverse effects, Invest Radiol, 2006;41: 651-60
20. Barrett B, Thomsen H, Katzberg R, Nephrotoxicity of lowosmolar iopamidol vs iso-osmolar iodixanol in renally impaired patients: the IMPACT study, Invest Radiol, 2006;41:815-21
21. Sutton AGC, Finn P, Grech ED, et al. Early and late reactions after the use of iopamidol 340, ioxaglate 320, and iodixanol 320 in cardiac catheterization, Am Heart J, 2001;141:677-83
22. Plavix (clopidogrel) package insert, New York, NY: Sanofi-Synthelabo, Inc., 2005
23. Briguori C, Colombo A, Airoldi F, et al. Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures, Catheter Cardiovasc Interv, 2006;67: 175-80
24. Grobner T, Prischl FC, Gadolinium and nephrogenic systemic fibrosis, Kidney Int, 2007;72(3):260-64
25. Deo A, Fogel M, Cowper SE, Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure, Clin J Am Soc Nephrol, 2007;2:264-7
26. Perazella MA, Rodby RA, Gadolinium-induced nephrogenic systemic fibrosis in patients with kidney disease, Am J Med, 2007;120:561-2